ArticleFrontiers in oncology2026
CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cytoskeleton-associated protein 2-like (CKAP2L), a microtubule-associated protein that serves as a structural component of the spindle pole and a cell cycle-related protein, acts as an oncogene in several cancers. This study seeks to elucidate the role of CKAP2L in endometrial cancer (EC) and to investigate its underlying mechanisms. Methods: The correlation between CKAP2L and clinical features was analyzed utilizing bioinformatics approaches. The expression of CKAP2L, Ki-67, and PCNA was evaluated using immunohistochemistry. Xenograft mouse models were established for Results: CKAP2L was elevated in EC tissues. Conclusions: CKAP2L enhances the malignant behavior and actin cytoskeleton remodeling of EC cells by decreasing AKT ubiquitination, sustaining AKT phosphorylation, and activating the PI3K/AKT signaling pathway. This indicates that CKAP2L could be a promising therapeutic target for EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.